SHAREHOLDER ALERT: EGBN EVH MGNX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / September 16, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Eagle Bancorp, Inc. (NASDAQ:EGBN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/eagle-bancorp-inc-loss-submission-form?prid=3527&wire=1
Lead Plaintiff Deadline: September 23, 2019
Class Period: March 2, 2015 to July 17, 2019

Allegations against EGBN include that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Evolent Health, Inc. (NYSE:EVH)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/evolent-health-inc-loss-submission-form?prid=3527&wire=1
Lead Plaintiff Deadline: October 7, 2019
Class Period: March 3, 2017 to May 28, 2019

Allegations against EVH include that: (1) Evolent's partnership model was not aligned with its partners, as it was designed to parasitically increase its own revenue by extracting enormous administrative and management fees at the expense of its partners such as Passport Health Plan ("Passport"); (2) Passport was struggling financially, particularly after Kentucky cut its reimbursement rates, and the partnership between Evolent and Passport was becoming increasingly unsustainable; (3) Evolent was draining Passport of functions, employees, and money to such an extent that Passport was left on the verge of insolvency; (4) for several months, Passport was conducting a bidding process to sell itself to a financial buyer to prevent liquidation; and (5) as a result of the foregoing, Defendants public statements were materially false and/or misleading and/or lacked a reasonable basis.

MacroGenics, Inc. (NASDAQGS:MGNX)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/macrogenics-inc-loss-submission-form?prid=3527&wire=1
Lead Plaintiff Deadline: November 12, 2019
Class Period: February 6, 2019 to June 3, 2019

Allegations against MGNX include that: (a) the Company had conducted the progression-free survival (“PFS”) and first interim overall survival (“OS”) analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong